PURPOSE: Radioimmunotherapy combines biologic and radiolytic mechanisms to target
and destroy tumor cells, thus offering a needed therapeutic alternative for refractory non-…

PURPOSE: Rituximab is commonly used as a single agent or in combination therapy for non-Hodgkin’s
lymphoma (NHL). Ibritumomab tiuxetan radioimmunotherapy targets the same …

Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was
evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including …

Purpose The primary purposes of eligibility criteria are to protect the safety of trial participants
and define the trial population. Excessive or overly restrictive eligibility criteria can slow …

Mildly thrombocytopenic patients with relapsed or refractory low-grade non-Hodgkin lymphoma
(NHL) have an increased risk of chemotherapy-induced myelosuppression following …

Umbilical cord blood (UCB) is a valuable source of hematopoietic stem cells (HSCs) for use
in allogeneic transplantation. Key advantages of UCB are rapid availability and less …

Purpose: Radioimmunotherapy (RIT) with yttrium-90 ( 90 Y)-labeled anti-CD20 antibody ( 90
Y ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) has a …

Introduction Chromosomal rearrangements involving neurotrophic tyrosine kinase 1 (NTRK1)
occur in a subset of non-small cell lung cancers (NSCLCs) and other solid tumor …

Mixed lymphohematopoietic chimerism can be induced in mice with bone marrow transplantation
(BMT) after a nonmyeloablative preparative regimen that includes cyclophosphamide, …

Although KIF5B–RET is the most common RET fusion in NSCLCs, RET inhibition with RXDX-105
resulted in responses only in non– KIF5B–RET -containing cancers. Novel approaches …